{
    "nctId": "NCT03364036",
    "officialTitle": "A 2-year Prospective Study to Evaluate the Onset of Action of Mavenclad\u00ae in Subjects With Highly Active Relapsing Multiple Sclerosis (MAGNIFY)",
    "inclusionCriteria": "* Highly active RMS as defined by:\n* One relapse in the previous year and at least 1 T1 Gadolinium (Gd)+ lesion or 9 or more T2 lesions, while on therapy with other disease modifying drugs (DMDs)\n* Two or more relapses in the previous year, whether on DMD treatment or not.\n* Expanded Disability Status Scale (EDSS) score less than equals to (\\<=) 5.0.\n* Other protocol defined inclusion criteria could apply.\n* Must have minimum age of 18 Years",
    "exclusionCriteria": "* Previous exposure to drugs such as fingolimod, natalizumab, alemtuzumab, mitoxantrone and ocrelizumab.\n* Positive hepatitis C or hepatitis B surface antigen test and/or hepatits B core antibody test for immunoglobulin G (IgG) and/or immunoglobulin M (IgM).\n* Current or previous history of immune deficiency disorders including a positive human immunodeficiency virus (HIV) result.\n* Currently receiving immunosuppressive or myelosuppressive therapy with, for example, monoclonal antibodies, methotrexate, cyclophosphamide, cyclosporine or azathioprine, or chronic use of corticosteroids.\n* History of tuberculosis , presence of active tuberculosis, or latent tuberculosis\n* Evidence or suspect of Progressive Multifocal Leukoencephalopathy (PML) in Magnetic Resonance Imaging (MRI).\n* Active malignancy or history of malignancy.\n* Other protocol defined exclusion criteria could apply."
}